Abstract: Compounds, compositions and methods are provided for inhibiting FAK mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding FAK. Methods of using these antisense compounds for inhibition of FAK expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of FAK are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3 kinase p110 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p110 beta. Methods of using these compounds for modulation of PI3 kinase p110 beta expression and for treatment of diseases associated with expression of PI3 kinase p110 beta are provided.

Abstract: The present invention provides novel compositions that show potent antiviral activity against both DNA and RNA viruses. In particular, the present invention provides oligo- and polyribonucleotides with potent antiviral activity against HIV and HCMV. These compositions are thought to operate in a novel fashion at an early stage of viral infection, meeting the need for alternatives or synergistic therapies to the toxic treatments currently available. The present invention also discloses methods for synthesizing oligo- and polyribonucleotides showing antiviral activity.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fra-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fra-1. Methods of using these compounds for modulation of fra-1 expression and for treatment of diseases associated with expression of fra-1 are provided.

Abstract: Oligonucleotides of the formula:5'-(CAP)-(Oligo)-(CAP)-3'are disclosed where (oligo) is a nucleotide sequence of from 10 to 40 nucleotides in length, and CAP is G.sub.m, where m is an integer of from zero to ten, the two CAP's which are present in the molecule can be defined independently of each other and must be different in the case where m is zero at the 5' or 3' end and the end of the oligo sequence is other than guanine. The oligonucleotides can be synthesized chemically. The oligonucleotides are used to diagnose or treat cancer, restenosis, a disease caused by a virus, a disease affected by integrins or cell-cell adhesion receptor or a disease triggered by diffusible factors.

Abstract: A synthetic nuclease resistant antisense oligodeoxynucleotide (AS-ODN) capable of selectively modulating human acetylcholinesterase (AChE) production and a composition comprising at least one AS-ODN as an active ingredient. A nuclease resistant antisense targeted against the splice junction in the AChE mRNA post-splice message is disclosed. The synthetic nuclease resistant AS-ODNs are capable of selectively modulating human AChE production in the central nervous system or capable of selectively reducing human AChE deposition of the neuromuscular junction. The present invention also provides a method to restore balanced cholinergic signalling in the brain and spinal cord or reduce AChE in the neuromuscular junction in patients in need of such treatment by administering to a patient in need of such treatment a therapeutically effective amount of at least one of the synthetic nuclease resistant AS-ODN capable of selectively modulating human AChE production.

Abstract: A synthetic nuclease resistant antisense oligodeoxynucleotide (AS-OND) capable of selectively modulating human acetylcholinesterase production in the central nervous system is provided. In an embodiment the antisense oligodeoxynucleotide can be selected from5'ACGCTTTCTTGAGGC 3' SEQ ID No:1, or - 5'GGCACCCTGGGCAGC 3' SEQ ID No:2.The present invention also discloses a pharmaceutical or medical composition comprising as active ingredient at least one synthetic nuclease resistant antisense oligodeoxynucleotide capable of selectively modulating human acetylcholinesterase production in the central nervous system in a physiologically acceptable carrier or diluent.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-S1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-S1. Methods of using these compounds for modulation of G-alpha-S1 expression and for treatment of diseases associated with expression of G-alpha-S1 are provided.

Abstract: Human E3 ubiquitin protein ligase is described. A structural region which encodes the polypeptide is disclosed as well as the the amino acid residue sequence of the protein ligase. Methods are provided which employ the sequences to identify compounds that modulate a biological and/or pharmacological activity of the molecule and hence regulate cellular and tissue physiology. The invention is also drawn toward the diagnosis, prevention, and treatment of pathophysiological disorders mediated by E3 ubiquitin protein ligases.

Abstract: Methods are provided for preparing a double-stranded cDNA corresponding to the 5' end of an mRNA. In the subject methods, an mRNA is first contacted with an oligo dT primer under first strand cDNA synthesis conditions. Next, the resultant hybrid is contacted with a random primer under first strand cDNA synthesis conditions, such that a cDNA complementary to the 5' end of the mRNA is produced. The resultant hybrid molecule is converted to two different double-stranded cDNAs, a first cDNA comprising the oligo dT primer and a second cDNA lacking the oligo dT primer. The two double-stranded cDNAs are then separated from each other. The subject methods find use in a variety of applications, and find particular use in the synthesis of 5' enriched cDNA libraries. Also provided are cDNA libraries produced by the subject methods, as well as kits for performing the subject methods.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Jun N-terminal Kinase Kinase-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Jun N-terminal Kinase Kinase-2. Methods of using these compounds for modulation of Jun N-terminal Kinase Kinase-2 expression and for treatment of diseases associated with expression of Jun N-terminal Kinase Kinase-2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Ets-2. The compositions comprise antisense com ounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ets-2. Methods of using these compounds for modulation of Ets-2 expression and for treatment of diseases associated with expression of Ets-2 are provided.